Hepatology · 1985 · 20 citations · 28 references
MedicinePharmacotherapyDissolution TestingHepatic PharmacotherapyHepatologyBile Acid MetabolismBiliary Tract DiseaseBiliary Tract DisordersCholesterol MetabolismHepatobiliary DiseaseLiver DiseaseGallstone Disease SurgeryRadiolucent Lesions
The Sunnybrook Gallstone Study was a randomized, double-blind, controlled trial of chenodeoxycholic acid treatment over 2 years in 160 patients with radiolucent gallstones. Sixty-four patients received 750 mg daily, 53 received 375 mg daily and 43 received placebo. Total dissolution of gallstones occurred in 10.9% of patients on 750 mg daily, 13.2% of those on 375 mg daily and in no patient on placebo. The drug was tolerated well. Diarrhea severe enough to cause withdrawal from the study occurred in two patients. No patient developed clinically significant hepatotoxicity. Serum cholesterol rose 10% or more above baseline after 2 years in 33% of patients treated with chenodeoxycholic acid and in 30% of those on placebo. Cholecystectomy was performed in 10.9% of patients on 750 mg daily, 17% on 375 mg daily and 13.6% on placebo. Chenodeoxycholic acid given at these doses dissolved radiolucent gallstones safely but the efficacy was limited.
28
Bixia Liu, Jieer Ying, Cong Luo et al. · Hepatogastroenterology · 2012 · 1.3K citations
Dissolution of Cholesterol Gallstones by Chenodeoxycholic Acid
R. G. Danzinger, Alan F. Hofmann, Leslie J. Schoenfield et al. · New England Journal of Medicine · 1972 · 657 citations
DISSOLUTION OF CHOLESTEROL GALLSTONES BY URSODEOXYCHOLIC ACID
S NAKAGAWA · The Lancet · 1977 · 305 citations
Chenodeoxycholic Acid Treatment of Gallstones
J. H. Iser, R. H. Dowling, Henry Mok et al. · New England Journal of Medicine · 1975 · 196 citations